Christel Herold-Mende

List of Publications by Year
in descending order

150	12,796	66343	26613
papers	citations	42 h-index	107 g-index

154	154	154	16522
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. Neuro-Oncology, 2022, 24, 39-51.	1.2	22
2	Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. International Journal of Radiation Oncology Biology Physics, 2022, 112, 499-513.	0.8	10
3	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death. Cancers, 2022, 14, 339.	3.7	6
4	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	5.2	12
5	Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy. Cancers, 2022, 14, 684.	3.7	2
6	Luminescent Pyrroleâ€based Phosphaphenalene Gold Complexes: A Versatile Anticancer Tool with a Wide Applicability. Chemistry - A European Journal, 2022, , .	3.3	5
7	Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. Acta Neuropathologica, 2022, 143, 609-612.	7.7	19
8	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	7.7	18
9	The genomic and transcriptional landscape of primary central nervous system lymphoma. Nature Communications, 2022, 13, 2558.	12.8	52
10	HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. Neuro-Oncology, 2022, , .	1.2	4
11	Diagnostic potential of extracellular vesicles in meningioma patients. Neuro-Oncology, 2022, 24, 2078-2090.	1.2	6
12	Luminescent Pyrroleâ€Based Phosphaphenalene Gold Complexes: Versatile Anticancer Tools with Wide Applicability. Chemistry - A European Journal, 2022, 28, .	3.3	4
13	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. Neuro-Oncology, 2022, 24, i168-i169.	1.2	0
14	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92.	1.2	0
15	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro-Oncology, 2021, 23, 226-239.	1.2	22
16	An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment. Cancers, 2021, 13, 568.	3.7	3
17	Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. International Journal of Molecular Sciences, 2021, 22, 2960.	4.1	4
18	Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients. Cancers, 2021, 13, 1601.	3.7	2

#	Article	IF	Citations
19	Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines. Cancers, 2021, 13, 1327.	3.7	5
20	Cannabidiol converts NF-Î¹B into a tumor suppressor in glioblastoma with defined antioxidative properties. Neuro-Oncology, 2021, 23, 1898-1910.	1.2	24
21	PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme.. Journal of Clinical Oncology, 2021, 39, 2041-2041.	1.6	1
22	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Letters, 2021, 506, 1-10.	7.2	17
23	A New Pentafluorothio-Substituted Curcuminoid with Superior Antitumor Activity. Biomolecules, 2021, 11, 947.	4.0	6
24	Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide. Cancers, 2021, 13, 3577.	3.7	12
25	Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study. Cancers, 2021, 13, 3435.	3.7	2
26	IDH1 mutations induce organelle defects via dysregulated phospholipids. Nature Communications, 2021, 12, 614.	12.8	44
27	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	7.7	31
28	The anesthetistâ€™s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. Neurosurgical Review, 2021, 44, 2707-2715.	2.4	9
29	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
30	Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers, 2021, 13, 5898.	3.7	7
31	Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. Neuro-Oncology, 2020, 22, 480-492.	1.2	31
32	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	7.7	45
33	Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. International Journal of Molecular Sciences, 2020, 21, 7801.	4.1	8
34	Gold(<scp>i</scp>) complexes based on six-membered phosphorus heterocycles as bio-active molecules against brain cancer. Chemical Communications, 2020, 56, 14593-14596.	4.1	6
35	Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. Cancer & Metabolism, 2020, 8, 23.	5.0	14
36	Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. Cancers, 2020, 12, 2583.	3.7	6

#	Article	IF	Citations
37	AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications, 2020, 11, 6366.	12.8	24
38	Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers, 2020, 12, 3270.	3.7	8
39	Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents. Cells, 2020, 9, 1389.	4.1	17
40	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 1931.	4.1	20
41	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica, 2020, 140, 409-413.	7.7	116
42	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neuro-Oncology Advances, 2020, 2, vdz060.	0.7	8
43	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. International Journal of Cancer, 2019, 145, 3436-3444.	5.1	8
44	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	7.7	104
45	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers, 2019, 11, 1072.	3.7	16
46	Volumetric assessment of glioblastoma and its predictive value for survival. Acta Neurochirurgica, 2019, 161, 1723-1732.	1.7	18
47	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	7.7	42
48	Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. Cancer Immunology, Immunotherapy, 2019, 68, 2005-2014.	4.2	24
49	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. Cancers, 2019, 11, 122.	3.7	25
50	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	1.2	102
51	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica, 2019, 138, 497-504.	7.7	57
52	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
53	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathologica, 2019, 138, 295-308.	7.7	74
54	DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer. Clinical Epigenetics, 2019, 11, 67.	4.1	19

#	Article	IF	Citations
55	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. Acta Neuropathologica, 2019, 138, 275-293.	7.7	6
56	Impact of post-surgical freezing delay on brain tumor metabolomics. Metabolomics, 2019, 15, 78.	3.0	9
57	ï»¿Preclinical evaluation of peptide-based radiotracers for integrin Î±vÎ²6-positive pancreatic carcinoma. Nuklearmedizin - NuclearMedicine, 2019, 58, 309-318.	0.7	8
58	Identification of KIF11 As a Novel Target in Meningioma. Cancers, 2019, 11, 545.	3.7	31
59	Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. Cell Metabolism, 2019, 30, 274-289.e5.	16.2	115
60	Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature Communications, 2019, 10, 1787.	12.8	379
61	Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. Neurosurgery, 2019, 85, E722-E729.	1.1	17
62	Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. Cancers, 2019, 11, 284.	3.7	18
63	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell, 2019, 35, 692-704.e12.	16.8	172
64	PET/CT Imaging of NSCLC with a Î±vÎ²6 Integrin-Targeting Peptide. Molecular Imaging and Biology, 2019, 21, 973-983.	2.6	21
65	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 2019, 11, 2028.	3.7	23
66	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	7.0	55
67	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	1.2	100
68	Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight, 2019, 4, .	5.0	63
69	Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes.. Journal of Clinical Oncology, 2019, 37, 2012-2012.	1.6	3
70	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
71	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
72	Comparison of the RGD Motifâ€“Containing Î±_vÎ²₆ Integrinâ€“Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. Journal of Nuclear Medicine, 2018, 59, 1679-1685.	5.0	38

#	Article	IF	Citations
73	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	7.7	109
74	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationâ€"the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	1.2	32
75	MetaboDiff: an R package for differential metabolomic analysis. Bioinformatics, 2018, 34, 3417-3418.	4.1	41
76	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	5.2	28
77	Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway. Cancer Letters, 2018, 428, 69-76.	7.2	12
78	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
79	A PRDX1â€p38Î± heterodimer amplifies METâ€driven invasion of IDHâ€wildtype and IDHâ€mutant gliomas. International Journal of Cancer, 2018, 143, 1176-1187.	5.1	14
80	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. Clinical Cancer Research, 2018, 24, 2951-2962.	7.0	25
81	DDIS-21. KIF11 INHIBITORS FILANESIB AND ISPINESIB AS NOVEL AGENTS FOR MENINGIOMA THERAPY. Neuro-Oncology, 2018, 20, vi73-vi73.	1.2	0
82	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i130-i130.	1.2	0
83	SURG-19. IMPACT OF INTRAOPERATIVE MAGNETIC RESONANCE IMAGING ON THE EXTENT OF RESECTION AND FUNCTIONAL OUTCOME IN AWAKE SURGERY FOR ELOQUENT GLIOMAS â€" A SINGLE CENTER RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, vi254-vi254.	1.2	0
84	Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma. Head and Neck, 2018, 40, 2685-2694.	2.0	6
85	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. Cancers, 2018, 10, 486.	3.7	11
86	Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. International Journal of Molecular Sciences, 2018, 19, 2903.	4.1	30
87	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	7.7	11
88	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	7.7	195
89	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	7.7	56
90	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	30.7	359

#	Article	IF	Citations
91	When Immune Cells Turn Badâ€"Tumor-Associated Microglia/Macrophages in Glioma. International Journal of Molecular Sciences, 2018, 19, 436.	4.1	231
92	Clinical and immunological correlates of long term survival in glioblastoma. Wspolczesna Onkologia, 2018, 2018, 81-85.	1.4	15
93	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making â€" A Selected Case Series. Klinische Padiatrie, 2018, 230, 305-313.	0.6	8
94	The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma. PLoS ONE, 2018, 13, e0193242.	2.5	8
95	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	7.7	146
96	Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. Cancer Immunology, Immunotherapy, 2017, 66, 593-603.	4.2	19
97	Identification of a Novel ITGÎ±vÎ²6-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research, 2017, 23, 4170-4180.	7.0	37
98	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Acta Neuropathologica, 2017, 134, 155-158.	7.7	26
99	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	1.2	39
100	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. Acta Neuropathologica, 2017, 134, 297-316.	7.7	23
101	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	10.7	586
102	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	7.7	12
103	Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine, 2017, 58, 27S-33S.	5.0	16
104	Helping EGFR inhibition to block cancer. Nature Neuroscience, 2017, 20, 1035-1037.	14.8	9
105	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Journal of Clinical Investigation, 2017, 127, 1425-1437.	8.2	334
106	VXM01 phase I study in patients with resectable progression of a glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2061-2061.	1.6	4
107	Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. Viruses, 2016, 8, 138.	3.3	19
108	Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget, 2016, 7, 31955-31971.	1.8	69

#	Article	IF	Citations
109	LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wildâ€type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432.	5.1	18
110	Radiogenomics of Glioblastoma: Machine Learningâ€“based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology, 2016, 281, 907-918.	7.3	236
111	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naÃ¯ve patients. BMC Cancer, 2016, 16, 81.	2.6	51
112	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. Journal of Neuro-Oncology, 2016, 129, 319-328.	2.9	25
113	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
114	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.6	62
115	Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. Clinical Neurology and Neurosurgery, 2016, 142, 72-80.	1.4	26
116	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
117	Non-invasive glioblastoma immunoprofiling by printed peptide arrays. OncoImmunology, 2016, 5, e1069941.	4.6	3
118	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	6.3	283
119	Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 112-119.	0.8	46
120	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NÂ²MÂ²).. Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	1.6	4
121	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 2016, 7, 14551-14568.	1.8	36
122	Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts. Anticancer Research, 2016, 36, 1489-96.	1.1	6
123	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia, 2015, 63, 1850-1859.	4.9	13
124	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	7.7	74
125	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
126	Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. Anticancer Research, 2015, 35, 2681-90.	1.1	0

#	Article	IF	Citations
127	Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e108908.	2.5	22
128	Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biology and Therapy, 2014, 15, 436-442.	3.4	7
129	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
130	Aberrant selfâ€renewal and quiescence contribute toÂtheÂaggressiveness of glioblastoma. Journal of Pathology, 2014, 234, 23-33.	4.5	53
131	Long Noncoding RNA TARID Directs Demethylation and Activation of the Tumor Suppressor TCF21 via GADD45A. Molecular Cell, 2014, 55, 604-614.	9.7	242
132	Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. International Journal of Cancer, 2014, 135, 2727-2734.	5.1	38
133	Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells. Current Pharmaceutical Design, 2014, 20, 66-72.	1.9	4
134	Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1065-1074.	1.7	10
135	Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. Radiology and Oncology, 2013, 47, 330-337.	1.7	29
136	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. PLoS ONE, 2012, 7, e41298.	2.5	43
137	Epigenetically mediated downregulation of the differentiationâ€promoting chaperon protein CRABP2 in astrocytic gliomas. International Journal of Cancer, 2012, 131, 1963-1968.	5.1	18
138	Association of Stem Cell-Related Markers and Survival in Astrocytic Gliomas. Biomarkers, 2011, 16, 136-143.	1.9	46
139	Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Science, 2011, 102, 387-392.	3.9	38
140	Expression and regulation of AC133 and CD133 in glioblastoma. Glia, 2011, 59, 1974-1986.	4.9	40
141	Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-Î². Clinical Cancer Research, 2011, 17, 4296-4308.	7.0	290
142	Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells. Clinical Cancer Research, 2010, 16, 2715-2728.	7.0	279
143	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 2009, 118, 469-474.	7.7	1,020
144	Antiglioma activity of 2,2â€²:6â€²,2Ê°-terpyridineplatinum(II) complexes in a rat modelâ€”Effects on cellular redox metabolism. Free Radical Biology and Medicine, 2006, 40, 763-778.	2.9	37

#	Article	IF	Citations
145	Different angiogenic phenotypes in primary and secondary glioblastomas. International Journal of Cancer, 2006, 118, 2182-2189.	5.1	126
146	Mechanistic Studies on a Novel, Highly Potent Gold-Phosphole Inhibitor of Human Glutathione Reductase. Journal of Biological Chemistry, 2005, 280, 20628-20637.	3.4	78
147	Antitumor Immunization of Head and Neck Squamous Cell Carcinoma Patients with a Virus-Modified Autologous Tumor Cell Vaccine. , 2004, 62, 173-183.		18
148	Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncology, 2004, 40, 28-35.	1.5	28
149	Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. International Journal of Cancer, 1999, 80, 194-198.	5.1	70
150	EXPRESSION OF CD44 SPLICE VARIANTS IN SQUAMOUS EPITHELIA AND SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK. , 1996, 179, 66-73.		79